Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors
Raskin, N Hiligsmann, M Rebutoc, A R Bansback, N Boonen, A Buchbinder, R Falahee, M Fraenkel, L Marshall, D A Maxwell, L
Raskin, N
Hiligsmann, M
Rebutoc, A R
Bansback, N
Boonen, A
Buchbinder, R
Falahee, M
Fraenkel, L
Marshall, D A
Maxwell, L
Affiliation
Maastricht University; University of Calgary; University of British Columbia; Arthritis Research Canada; Monash University; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; Yale University; Berkshire Health Systems; University of Ottawa; Ottawa Hospital Research Institute; McMaster University; Canadian Arthritis Patient Alliance; University of Toronto; Institute for Work & Health Toronto; University Hospitals Bristol and Weston NHS Foundation Trust; Humaintas University; Université de Lorraine
Other Contributors
Publication date
2025-06-06
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Interest in standardizing descriptions of health outcomes is increasing. In a Health Outcome Descriptor (HOD), outcomes are systematically described covering four domains: Symptoms, Time horizon, Testing and Treatment, and Consequences. Given the lack of HODs for Rheumatoid Arthritis (RA), the aim of this study was to review published RA outcome descriptions and map them to the HOD framework.
Methods: We conducted a rapid review of patient-decision aids (PtDAs) and patient preference studies to assess how seven RA outcomes have been described in English to patients. These outcomes were selected by author consensus, from a living systematic review of RA drug therapy. After data extraction and a thematic content analysis, a narrative summary for each outcome was provided.
Results: We included 11 PtDAs and 27 patient preference studies. Overall, the descriptions of the same health outcome varied widely across studies. Adverse events (AEs) were described in most cases (N = 26/38). For both PtDAs and preference studies, few provided a description for patient-important outcomes like remission (N = 2/11 and N = 1/27 respectively) and pain (N = 2/11 and N = 6/27 respectively). From an HOD perspective, the descriptions focused primarily on symptoms patients may experience (94 %), and less on the other domains (18-38 %).
Conclusion: There is wide variability in the content of the published RA outcome descriptions, as well as a lack of descriptions regarding common patient-important outcomes. As this study provides a detailed overview of existing descriptions, it may inform future development of HODs for RA.
Citation
Raskin N, Hiligsmann M, Rebutoc AR, Bansback N, Boonen A, Buchbinder R, Falahee M, Fraenkel L, Marshall DA, Maxwell L, Nieuwlaat R, Proulx L, Saadat P, Shea B, Tugwell P, Wiercioch W, Beaton D, Richards P, Schünemann H, Guillemin F, Hazlewood GS. Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Semin Arthritis Rheum. 2025 Oct;74:152769. doi: 10.1016/j.semarthrit.2025.152769. Epub 2025 Jun 6.
Type
Article